RC2NB researchers among the world's most cited! Congrats to Prof. Jens Kuhle & Prof. Ludwig Kappos Ludwig Kappos from RC2NB & UniSpitalBaselCH for being named Highly Cited Researchers in #Neuroscience & #Behaviour! 🧠 Your work inspires us all! Full list: lnkd.in/grnCUJsX

oin us this Saturday! 🌟 Be part of “Learning from Patient Care for Research & Therapies,” hosted by the MS Center & RC2NB. 📅 Dec 7, 2024 📍 ZLF, University Hospital Basel 🔹 Insights on MS research 🔹 Latest treatments 🔹 Community connections Check out the agenda below!

Ending the Year on a High Note! Prof. Jens Kuhle (UniSpitalBaselCH) has been awarded the Sobek Foundation Award 2024, Europe’s most prestigious honor in MS research! A remarkable recognition for his work on biomarkers transforming MS care. University of Basel #MultipleSclerosis

On Dec 7, the MS Centre Basel UniSpitalBaselCH & #RC2NB hosted “Learning from Patient Care for Research and Therapies.” A day filled with inspiring talks and lively exchanges during the apero & expert sessions. Thank you to all who joined and made this event a success! #MSresearch

🎉 Starting 2025 on a high note! Congrats to Dr. Andreea Alexandra Aldea on winning the YTCR grant for her study on choroid plexus volume in MS, mentored by Prof. Özgür Yaldizli. Backed by the RC2NB & @ThINk_Basel teams, this project promises exciting insights! 🔬#MSresearch

🎉 First paper of 2025 is out! 🧠 "Aberrant complement activation is associated with structural brain damage" (Oechtering et al.) highlights the link between complement activation, brain volume loss, lesion progression, and severe MS. Read more: pubmed.ncbi.nlm.nih.gov/39752618/ #RC2NB

Authors developed and validated SMARTCARE-EDSS training method to enable health care professionals to assess disability for decentralized trials in #MultipleSclerosis. A Swiss multicenter, randomized, cross-over study from UniSpitalBaselCH RC2NB ▶️ journals.sagepub.com/doi/full/10.11…

🚀 Excited to share our latest Journal of Neurology publication on dreaMS app. Six gamified, adaptive cognitive tests (<10 min) improve sensitivity to change by addressing floor/ceiling & practice effects. Big thanks to our team & partners! Read more: link.springer.com/article/10.100…

🚨 New in Nature Reviews Neurology! 🎉 AHSCT for MS & NMOSD gets key insights from ECTRIMS & European Society for Blood and Marrow Transplantation. Game-changing treatment guidance! nature.com/articles/s4158…

🧠 This Saturday, Jan 25, join the Swiss MS Society’s State of the Art Symposium 2025: "Lifestyle in MS – Modifiable Factors to Enhance Brain Health." 📍 KKL Luzern ⏰ 09:30 – 16:00 Join our team and many other experts! multiplesklerose.ch/de/ueber-ms/fa…

RC2NB joined the MS State of the Art Symposium 2025 on "Lifestyle in MS: Sports, Nutrition, & Brain Health." Proud to see @ThINk_Basel & Jens Kuhle represent RC2NB, with our team sharing research on: 🔬 MultiSCRIPT 🔬 Complement activation in MS 🔬 B cell therapies

Feb 11 – International Day of Women & Girls in Science! 🚀 At #RC2NB & @ThINk_Basel , this day is every day. Leading the way? Prof. Cristina Granziera, championing brilliant women who shape the future of #STEM.🔬💡 #WomenInScience #IDWGS #MSresearch

We are pleased to present the RC2NB Annual Report 2024, highlighting a year of progress, key milestones, and scientific advancements across our four core workstreams. 📖 Read the full report here: rc2nb.ch/wp-content/upl…

In RC2NB’s Annual Report, real patient stories highlight why personalized treatments & cutting-edge research matter. Together, we’re shaping the future of MS care. #MS #Research #PatientVoices

Just 24 participants to go: Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year. Only possible through full embedding in routine care and with an outstanding team RC2NB and #SMC and the wonderful support of our patients. multiscript.rc2nb.ch

🧠 New in Neurol Neuroimmunol Neuroinflamm: CSF TNF markers + early gray matter damage predict PIRA in early RRMS. Key predictors: sTNFR1, sTNFR2, LIGHT, cortical lesions, thalamic atrophy. 🔗pubmed.ncbi.nlm.nih.gov/40311103/#&gid… #MS #PIRA #Neuroinflammation #MRI #CSF #MultipleSclerosis

Functional System scores and their corresponding subscores, Ambulation scores and EDSS scores revealed different patterns of disability in #MultipleSclerosis. Machine learning study using EXPAND trial from RC2NB University of Basel UniSpitalBaselCH ▶️ journals.sagepub.com/doi/full/10.11…

🚀 Our new website is live! Explore RC2NB's research, people & purpose — now at RC2NB.ch 🧠✨ 🎬 Watch the RC2NB Welcome Video for a glimpse into our world. ▶️ vimeo.com/1090750659/132… #RC2NB #Neuroimmunology #MSResearch #WebsiteLaunch

MSIF is proud to announce Professor Ludwig Kappos as the 2025 #CharcotAward recipient, honouring a lifetime of impact in #MSResearch. 🏆🔬 From pioneering treatments to mentoring researchers worldwide, his legacy is global. 🌎 Read more: msintfederation.org/4ncra5K   RC2NB

🧪 New data from the phase 3 POINT study: combining ponesimod + dimethyl fumarate in relapsing MS did not improve relapse rate, but reduced MRI lesion activity vs DMF alone. Safety was consistent with known profiles. 📄 sciencedirect.com/science/articl…